In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Boehringer Ingelheim buys heartburn drug Zantac for $509.5mm

Executive Summary

As Johnson & Johnson continues to divest products to pave the way for its acquisition of Pfizer Consumer Health Care Group, the company and Pfizer have agreed to sell all US rights, title, and interest in Pfizer's OTC anti-ulcerant Zantac (ranitidine) to Boehringer Ingelheim Pharmaceuticals for $509.5mm in cash.
Deal Industry
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register